98 related articles for article (PubMed ID: 4032756)
61. [Phase I study of CI-898. CI-898 Study Group].
Taguchi T; Tsukagoshi S; Furue H; Niitani H; Ohta K; Ariyoshi H; Hasegawa K; Majima H; Nakao I; Yasutomi M
Gan To Kagaku Ryoho; 1991 Aug; 18(10):1599-612. PubMed ID: 1831340
[TBL] [Abstract][Full Text] [Related]
62. [In vitro evaluation of anticancer drugs and retrospective clinical trials with the human tumor cloning system].
Inoue K; Ogawa M; Mukaiyama T; Mitsui I; Inagaki J; Horikoshi N
Nihon Gan Chiryo Gakkai Shi; 1985 Feb; 20(1):59-65. PubMed ID: 3889195
[No Abstract] [Full Text] [Related]
63. [Human amniotic fluid research. In vitro antineoplastic activity].
Gheri Bryk S; Marchesi L; Di Preta F
Arch Ital Anat Embriol; 1981; 86(4):363-84. PubMed ID: 6890333
[No Abstract] [Full Text] [Related]
64. The current status of cancer chemotherapy for selected human neoplasms.
Rubin RN
Clin Ther; 1981; 4(2):74-94. PubMed ID: 7028265
[No Abstract] [Full Text] [Related]
65. Clinical correlations with the human tumor cloning assay.
Hanauske AR; Von Hoff DD
Cancer Invest; 1985; 3(6):541-51. PubMed ID: 3910194
[No Abstract] [Full Text] [Related]
66. The role of high dose chemotherapy in adult solid tumours other than breast cancer.
Hornedo J; Cortés-Funes H
Ann Oncol; 1996; 7 Suppl 2():23-30. PubMed ID: 8805946
[No Abstract] [Full Text] [Related]
67. In vitro short-term test to determine the resistance of human tumors to chemotherapy: Group for Sensitivity Testing of Tumors (KSST).
Cancer; 1981 Nov; 48(10):2127-35. PubMed ID: 7197581
[TBL] [Abstract][Full Text] [Related]
68. In vitro studies of human tumor and embryonic tissue.
Allen A; Ramon T; Jacobson A; Wade ME
Am J Obstet Gynecol; 1973 Jun; 116(4):463-9. PubMed ID: 4575509
[No Abstract] [Full Text] [Related]
69. Differentiating agents in the treatment of human malignancies.
Cheson BD; Jasperse DM; Chun HG; Friedman MA
Cancer Treat Rev; 1986 Sep; 13(3):129-45. PubMed ID: 3536087
[No Abstract] [Full Text] [Related]
70. Cancer treatment today and its impact on drug development, with special emphasis on the phase II clinical trial.
Carter SK
J Natl Cancer Inst; 1976 Aug; 57(2):235-44. PubMed ID: 794496
[No Abstract] [Full Text] [Related]
71. Navelbine: a new step in cancer therapy?
Armand JP; Marty M
Semin Oncol; 1989 Apr; 16(2 Suppl 4):41-5. PubMed ID: 2652319
[No Abstract] [Full Text] [Related]
72. [SM-108].
Uzuka Y; Saito Y
Gan No Rinsho; 1985 May; 31(6 Suppl):757-66. PubMed ID: 4032756
[TBL] [Abstract][Full Text] [Related]
73. [Transition of criteria for the determination of efficacy of cancer chemotherapy].
Koyama Y
Gan To Kagaku Ryoho; 1986 Jan; 13(1):153-63. PubMed ID: 3942397
[No Abstract] [Full Text] [Related]
74. [Antitumor activities of orally administered 4-carbamoylimidazolium-5-olate (SM-108)].
Nakamura M; Fukui M; Morisada S; Inaba M; Tsukagoshi S; Sakurai Y
Gan To Kagaku Ryoho; 1985 Oct; 12(10):2030-6. PubMed ID: 4051519
[TBL] [Abstract][Full Text] [Related]
75. [Phase II study of SM-108 (4-carbamoylimidazolium-5-olate) in hematological malignancies].
Kimura K; Yamada K; Uzuka Y; Masaoka T; Hirano M; Ohno R; Ogawa M
Gan To Kagaku Ryoho; 1989 Jan; 16(1):123-30. PubMed ID: 2643392
[TBL] [Abstract][Full Text] [Related]
76. Optimal treatment schedule and antitumor spectrum of 4-carbamoylimidazolium 5-olate (SM-108) in murine tumors.
Yoshida N; Nakamura M; Fukui M; Morisada S; Ogino S; Inaba M; Tsukagoshi S; Sakurai Y
Cancer Res; 1983 Dec; 43(12 Pt 1):5851-6. PubMed ID: 6640536
[TBL] [Abstract][Full Text] [Related]
77.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
78.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
79.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
80.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
